Jiangsu Key Laboratory for Microbes and Functional Genomics, Jiangsu Engineering and Technology Research Center for Microbiology, College of Life Sciences, Nanjing Normal University, Nanjing, China.
Jiangsu Key Laboratory for the Research and Utilization of Plant Resources, Institute of Botany, Jiangsu Province and Chinese Academy of Sciences, Nanjing, China.
Appl Environ Microbiol. 2019 Apr 18;85(9). doi: 10.1128/AEM.00106-19. Print 2019 May 1.
Fungal infections not only cause extensive agricultural damage but also result in serious diseases in the immunodeficient populations of human beings. Moreover, the increasing emergence of drug resistance has led to a decrease in the efficacy of current antifungals. Thus, screening of new antifungal agents is imperative in the fight against antifungal drug resistance. In this study, we show that an endophytic bacterium, HDXY-02, isolated from the medicinal plant , showed broad-spectrum antifungal activity against plant and human fungal pathogens. An antifungal ability assay indicated that the bioactive component was produced from strain HDXY-02 having an extracellular secreted component with a molecular weight lower than 1,000 Da. In addition, we found that this new antifungal could be produced effectively by liquid fermentation of HDXY-02. Furthermore, the purified component contributing to the antifungal activity was identified to be toxoflavin, a yellow compound possessing a pyrimido[5,4-e][1,2,4]triazine ring. bioactivity studies demonstrated that purified toxoflavin from HDXY-02 cultures had a significant antifungal activity against the human fungal pathogen , resulting in abolished germination of conidia. More importantly, the growth inhibition by toxoflavin was observed in both wild-type and drug-resistant mutants ( and non-) of Finally, an optimized protocol for the large-scale production of toxoflavin (1,533 mg/liter) has been developed. Taken together, our findings provide a promising biosynthetic resource for producing a new antifungal reagent, toxoflavin, from isolates of the endophytic bacterium Human fungal infections are a growing problem associated with increased morbidity and mortality. Moreover, a growing number of antifungal-resistant fungal isolates have been reported over the past decade. Thus, the need for novel antifungal agents is imperative. In this study, we show that an endophytic bacterium, , isolated from the medicinal plant , is able to abundantly secrete a compound, toxoflavin, which has a strong fungicidal activity not only against plant fungal pathogens but also against human fungal pathogens and , , and the model filamentous fungus More importantly, toxoflavin also displays an efficacious inhibitory effect against azole antifungal-resistant mutants of Consequently, our findings provide a promising approach to abundantly produce toxoflavin, which has novel broad-spectrum antifungal activity, especially against those currently problematic drug-resistant isolates.
真菌不仅会造成广泛的农业损害,还会导致人类免疫缺陷人群患上严重疾病。此外,抗药性的不断出现导致了现有抗真菌药物疗效的下降。因此,筛选新的抗真菌剂对于对抗抗真菌药物耐药性至关重要。在这项研究中,我们展示了一种内生细菌,HDXY-02,从药用植物中分离出来,对植物和人类真菌病原体表现出广谱抗真菌活性。抗真菌能力测定表明,生物活性成分来自具有分子量低于 1000 Da 的细胞外分泌成分的菌株 HDXY-02。此外,我们发现这种新型抗真菌剂可以通过 HDXY-02 的液体发酵有效产生。此外,鉴定出对真菌活性有贡献的纯化成分是黄曲霉素,一种具有嘧啶并[5,4-e][1,2,4]三嗪环的黄色化合物。生物活性研究表明,从 HDXY-02 培养物中纯化的黄曲霉素对人类真菌病原体有显著的抗真菌活性,导致分生孢子的萌发被破坏。更重要的是,在野生型和耐药突变体(和非-)中观察到黄曲霉素的生长抑制作用。最后,开发了一种大规模生产黄曲霉素(1533mg/L)的优化方案。总之,我们的研究结果为从内生细菌中生产新型抗真菌试剂黄曲霉素提供了有前途的生物合成资源。
人类真菌感染是一个日益严重的问题,与发病率和死亡率的增加有关。此外,在过去十年中,报告了越来越多的抗真菌耐药真菌分离株。因此,需要新型抗真菌药物。在这项研究中,我们展示了一种内生细菌,从药用植物中分离出来,能够大量分泌一种化合物,黄曲霉素,它不仅对植物真菌病原体,而且对人类真菌病原体和具有很强的杀菌活性,和,以及丝状模型真菌。更重要的是,黄曲霉素对唑类抗真菌耐药突变体也显示出有效的抑制作用。因此,我们的研究结果为大量生产黄曲霉素提供了一种有前途的方法,黄曲霉素具有新型广谱抗真菌活性,特别是对那些目前存在问题的耐药分离株。